HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With ‘CBD HQ,' Vitamin Shoppe Reflects US Industry Confidence In Cannabidiols Market's Future

Executive Summary

Vitamin Shoppe rolls out CBD HQ sections in 572 stores in 39 states, citing strong word-of-mouth demand for products. The national retailer’s move could reflect growing bullishness by industry after FDA sent unpublished draft guidance on CBD enforcement for White House clearance.

You may also be interested in...



Vitamin Shoppe Reaches Vietnam With Partner Concerned About Quality Of Products In Country

Vitamin Shoppe’s license with Kim Lien opens two stores in Hanoi and plans to launch wholesale distribution of its proprietary brands. The Asian market in recent years has been plagued by fake supplements and unknown ingredient sources, Kim Lien says.

Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials

Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.

Unpublished And Under Review? US FDA’s CBD Policy Draft Guidance Still Has Industry Talking

Supplements containing hemp-derived cannabidiols aren’t typical products subject to FDA’s regulatory oversight, and the document stating its thinking on enforcement in the market submitted to the Office of Management and Budget isn’t a typical draft guidance.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel